Effect of the?? glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics

Abstract

BAY-g-5421 is an a-glucosidase-inhibitor which inhibits intestinal absorption of carbohydrates. In a double-blind cross over study 12 diabetics taking sulphonylureas and 12 insulin-treated diabetics were treated additionally with BAY-g-5421 or a placebo for two seven day periods. In the pretreatment period and on the 7th and 14th day of the treatment periods serial blood glucose profiles were measured. In comparison to placebo BAY-g-5421 significantly lowered the mean (140 versus 157 mg/dl) and the maximal (192 versus 230 mg/dl) blood glucose values and the integrated blood glucose response (3112 versus 3421 mg/dl 24h) in the sulphonylurea-treated group as well as in the insulin-treated group (mean blood glucose 161 versus 192 mg/dl, maximal blood glucose 238 versus 283 mg/dl, integrated blood glucose response 3109 versus 3857 mg/dl-24 h). The amplitude of glycaemic excursions was significantly decreased only in the sulphonylurea-treated group (96 versus 129 mg/dl), but not in the insulin-treated diabetics. No influence on routine liver function, renal ftmction or haematological tests was observed. Side effects included hypoglycaemia in 3 patients of the insulin-treated group and meteorism in both groups. BAY-g-5421 could be a useful additional treatment for diabetic patients.

Improvement of metabolic control in insulin dependent diabetics treated with the ?-glucosidase inhibitor Acarbose for two months

“…They observed that Acarbose diminished the post-prandial increases in blood glucose, lactate and pyruvate concentrations. Sachse and Willms [5] treated 12 insulin dependent diabetics for one week in a double-blind cross-over study comparing Acarbose with placebo. They reported that Acar-bose lowered the mean and the maximal blood glucose values as well as the "integrated blood glucose response".…”

“…Short-term metabolic studies have suggested that Acarbose may be a useful additional treatment for diabetic patients [5][6][7].The aim of the present study was to investigate the potential benefits of Acarbose in insulin dependent diabetics over a period of two months. The experiment was conducted with a single-blind protocol in which the patients were given a placebo for two months before and two months after the treatment period.…”

Effects of a glucoside-hydrolase inhibitor (Bay g 5421) on serum lipids, lipoproteins and bile acids, fecal fat and bacterial flora, and intestinal gas production in hyperlipidemic patients.

“…-glucoside-hydrolase in hibitor; serum lipoproteins; fecal flora; bile acids; meteorism A new glucoside-hydrolase inhibitor (Bay g 5421, Bayer AG, West Germany), when taken orally, is known to delay the intestinal absorption of starch and sucrose by inhibiting maltase and sucrase activities (Schmidt et al 1977;Puls et al 1977). Since this acarbose diminishes the postprandial increase of blood glucose, it may be of value in the management of diabetic patients (Walton et al 1979;Sachse and Willms 1979). Our previous study also revealed that the administration of the drug.…”

Long-term treatment of sulphonylurea-treated diabetics with the ?-glucosidase inhibitor Bay g 5421 (Acarbose)

“…Dear Sir, A lowered postprandial rise of blood glucose following the ingestion of an a-glucosidase inhibitor (Acarbose, Bay g 5421, [1]) has been described in patients with diabetes mellitus [2][3][4][5][6]. The drug appears to be less effective, however, following its prolonged administration in patients with Type 2 diabetes [3].…”